Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-19
2006-09-19
Tate, Christopher R (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S018700, C514S081000, C514S251000, C530S322000, C530S331000, C544S259000, C544S244000
Reexamination Certificate
active
07109165
ABSTRACT:
This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5334711 (1994-08-01), Sproat
patent: 5416016 (1995-05-01), Low et al.
patent: 5589332 (1996-12-01), Shih et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5631359 (1997-05-01), McSwiggen et al.
patent: 5633133 (1997-05-01), Long et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5716824 (1998-02-01), Beigelman
patent: 5741679 (1998-04-01), George et al.
patent: 5834186 (1998-11-01), George et al.
patent: 5849902 (1998-12-01), Arrow et al.
patent: 5871914 (1999-02-01), Nathan et al.
patent: 5989912 (1999-11-01), Arrow et al.
patent: 6001311 (1999-12-01), Brennan
patent: 6335434 (2002-01-01), Guzaev et al.
patent: 0 360 257 (1990-03-01), None
patent: WO 89/02439 (1989-03-01), None
patent: WO 90/12096 (1990-10-01), None
patent: WO 91/03162 (1991-03-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 93/15187 (1993-08-01), None
patent: WO 93/23569 (1993-11-01), None
patent: WO 95/11304 (1994-10-01), None
patent: WO 95/06731 (1995-03-01), None
patent: WO 95/11910 (1995-05-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 96/22689 (1996-08-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 98/13526 (1998-04-01), None
patent: WO 98/27104 (1998-06-01), None
patent: WO 98/28317 (1998-07-01), None
patent: WO 98/43993 (1998-10-01), None
patent: WO 98/56384 (1998-12-01), None
patent: WO 98/58058 (1998-12-01), None
patent: WO 99/16871 (1999-04-01), None
patent: WO 99/29842 (1999-06-01), None
patent: WO 99/54459 (1999-10-01), None
patent: WO 99/55857 (1999-11-01), None
patent: WO 99/66063 (1999-12-01), None
patent: WO 00/26226 (2000-05-01), None
Abramovitz et al., “Catalytic Role of 2′-Hydroxyl Groups Within a Group II Intron Active Site,”Science271:1410-1413 (1996).
Banerjee and Turner, “The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme,”Biochemistry34:6504-6512, (1995).
Beaudry and Joyce, “Directed Evolution of an RNA Enzyme,” Science 257:635-641 (1992).
Beigelman et al., U.S. Appl. No. 09/301,511, filed Apr. 28, 1999.
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes,” J. Biol Chem. 270:25702-25708 (1995.
Bellon et al., “Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes,”Nucleosides&Nucleotides16:951-954 (1997).
Bellon et al., “Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis,”Bioconjugate Chem.8:204-212 (1997).
Berzal-Herranz et al., Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme EBMO J. 12:2567-2574 (1993).
Berzal-Herranz et al., “In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions,” Genes & Development 6:129-134 (1992).
Bevilacqua et al., “A Mechanistic Framework for the Second Step of Splicing Catalyzed by the Tetrahymena Ribozyme,” Biochemistry 35:648-658 (1996).
Breaker, “Catalytic DNA: in training and seeking employment,”Nature Biotechnology17:422-423 (1999).
Breaker and Joyce, “Inventing and improving ribozyme function: rational design versus iterative selection methods,” TIBTECH 12:268-275 (1994).
Breaker et al., “A DNA enzyme with Mg2-dependent RNA phosphoesterase activity,”Chemistry&Biology2(10):655-660 (1995).
Breaker, “Are engineered proteins getting competition from RNA?” Current Opinion in Biotechnology 7:442-448 (1996).
Brennan et al., “Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis,”Biotechnology and Bioengineering(Combinatorial Chemistry) 61:33-45 (1998.
Brody and Gold, “Aptamers as therapeutic and diagnostic agents,”Reviews in Molecular Biotechnology74:5-13 (2000).
Burgin et al., “Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates,” Biochemistry 35:14090-14097 (1996) (vol. No. mistakenly listed as 6).
Burlina et al., “Chemical Engineering of Rnase Resistant and Catalytically Active Hammerhead Ribozymes,”Bioorganic&Medicinal Chemistry5:1999-2010 (1997).
Caruthers et al., “Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs,”Methods i Enzymology211:3-19 (1992).
Cech, “Ribozymes and Their Medical Implications,”JAMA260:3030-3034 (1988).
Chartrand et al., “An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain,” Nucleic Acids Research 23(20): 4092-4096 (1995).
Chowrira et al., “Novel guanosine requirement for catalysis by the hairpin ribozyme,” Nature 354:320-322 (1991).
Cload and Schepartz, “Polyether Tethered Oligonucleotide Probes,”J. Am. Chem. Soc.113:6324-6326 (1991).
Collins and Olive, “Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From Neurospor VS RNA,” Biochemistry 32:2795-2799 (1993).
Crooke, “Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides,”Advances in Pharmacology40:1-49 (1997).
Crooke, “Antisense Therapeutics,”Biotechnology and Genetic Engineering Reviews15:121-157 (1998).
Crooke, “Progress in Antisense Technology: The End of the Beginning,”Methods in Enzymology313:3-45 (1999).
Daniels et al., “Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of in Vitro Reaction Rates and Products,” J. Mol. Biol. 256:31-49 (1996).
Delihas et al., “Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design,”Nature Biotechnology15:751-753 (1997).
Durand et al., “Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of Hexaethylene Glycol Chain: Conformation and Stability,”Nucleic Acids Research18:6353-6359 (1990).
Duval-Valentin, “Specific inhibition of transcription by triple helix-forming oligonucleotides,”Proc. Natl. Acad Sci. USA89:504-508 (1992).
Earnshaw et al., “Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function,”Biopolymers48:39-55 (1998).
Egholm et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bondin rules,”Nature365:566-568 (1993).
Feldstein et al., “Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA,” Gene 82:53-61 (1989).
Ferentz and Verdine, “Disulfied Cross-Linked Oligonucleotides,”J. Am. Chem. Soc.113:4000-4002 (1991).
Forster and Altman, “External Guide Sequences for an RNA Enzyme,” Science 249:783-786 (1990).
Fox, “Targeting DNA with Triplexes,”Current Medicinal Chemistry7:17-37 (2000).
Freier et al., “Improved free-energy parameters for predictions of RNA duplex stability,”Proc. Natl. Acad. Sci USA83:9373-9377 (1986).
Godwin et al., “The Synthesis of Biologically Active Pteroyloligo-γ-L-Glutamates (Folic Acid Conjugates),”Biol. Chem., 247:2266-2271 (1972).
Gold et al., Diversity of Oligonucleotide Functions,Annu. Rev. Biochem.64:763-797 (1995).
Grasby et al., “Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA,” Biochemistry 34:4068-4076 (1995).
Griffin et al., “Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with
Beigelman Leonid
Matulic-Adamic Jasenka
Cordero Garcia Marcela M
McDonnell Boehnen & Hulbert & Berghoff LLP
Sirna Therapeutics, Inc.
Tate Christopher R
LandOfFree
Conjugates and compositions for cellular delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates and compositions for cellular delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates and compositions for cellular delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530996